Headline
Geoff Woo is Co-Founder and General Partner at Anti Fund, a contrarian early-stage vehicle with a documented focus on health, performance, and science-driven consumer and B2B companies.
---
Investor-Stage Fit
Score: 28/100. Public data on Anti Fund's stage mandate, check size, and geographic scope is sparse to the point of being operationally useless for a founder trying to forecast a yes. Woo's operator background (CEO of HVMN/Nootrobox, co-founder of Glassmap, acquired by Google) signals early-stage pattern recognition, but that inference is indirect and unconfirmed by fund disclosures.
- Stage clarity 8/25 — No fund documents, portfolio pages, or press interviews in the subject data confirm a stated stage preference; stage inference relies entirely on founder background. (Confidence: Low — single indirect signal.)
- Sector clarity 10/25 — HVMN's focus on nootropics, ketone esters, and human performance suggests health/biotech/consumer wellness affinity, but Anti Fund's public thesis is [insufficient public evidence as of 2026-05-17].
- Check-size discipline 5/25 — No check-size band, fund size, or portfolio round data is available in the subject data; a founder cannot calibrate raise size to this investor. (Confidence: Low.)
- Geographic clarity 5/25 — No location data is present in the subject record; geographic mandate is [insufficient public evidence as of 2026-05-17].
Pitch-Worthiness Score
Score: 22/100. The combination of near-zero public thesis signal, a reachability rating of Closed, and no documented investment activity in the last 12 months makes this a highly unlikely (10–20%) productive use of four weeks of founder outreach time (Confidence: Low — based on absence of public activity signals rather than confirmed negative). Woo's operator credibility is real, but credibility alone does not translate into a fundable thesis match without corroborating public evidence. Founders in health, performance science, or deep-tech consumer should note the HVMN connection as a weak positive signal, but should not build a fundraising strategy around it.
---
Top 3 Reasons to Pitch
- Operator-to-investor credibility in human performance. Woo co-founded and led HVMN (Nootrobox), a company that commercialised ketone esters and nootropics — direct domain experience that is rare among early-stage health/biotech investors.
- Anti Fund's contrarian positioning. Anti Fund's name and public identity signal appetite for non-consensus bets; founders with unconventional science-backed theses are likely (55–75%) to get a more receptive first read here than at a consensus-driven fund (Confidence: Low — inferred from brand positioning, not portfolio data).
- Early-stage operator empathy. Woo's background includes Glassmap, acquired by Google, suggesting he has navigated early product-market fit cycles personally — a signal that he likely understands pre-revenue risk tolerance.
Top 3 Reasons to Skip / Open Questions
- Reachability is Closed. Zero active X posts in the last period, no LinkedIn activity count, no public email, no contact form, and zero door-openers in the reachability index — a founder has no low-friction path to first contact as of 2026-05-17.
- Fund thesis is publicly invisible. No essays, blog posts, press interviews, or portfolio disclosures appear in the subject data; a founder cannot confirm sector fit, check size, or stage before investing outreach time. This is a remote chance (under 5%) of a cold pitch converting without a warm introduction (Confidence: Low).
- Comparable investor index mismatch. The five closest peer investors surfaced by the index are all edtech-focused — a sector with no documented connection to Woo's background — suggesting the index has low confidence in his actual peer group, which itself signals thin public data and makes due diligence harder for a founder.
Comparable Investors
- Litzie Maarek — [firm not listed] · *Public investor record*. Included as a structural peer (early-stage, science-adjacent thesis, non-consensus fund design), though sector overlap with Woo is unconfirmed.
- Gayle Jennings O'Byrne — WOCstar Fund · *Public investor record*. Operator-to-investor transition archetype with community-development roots; useful comparison for founders evaluating mission-driven early-stage GPs.
- Malvika Bhagwat — Owl Ventures · *Public investor record*. Evidence-based, outcomes-focused investment lens; relevant comparison for founders whose pitch relies on scientific validation rather than market-size narratives.
- Don Burton — LearnStart · *Public investor record*. Serial founder with an exit (Kaplan/Washington Post) who invests very early; structural archetype overlap with Woo's founder-turned-GP profile.
- Gayle Jennings-O'Byrne — [firm not listed] · *Public investor record*. Duplicate record in the index; treat as the same investor listed above — no additional signal.
Reachability
Open-Door Rating: Closed
Woo's X handle is `@geoffreywoo` but recorded zero posts in the last tracked period, making public engagement an unreliable path. No LinkedIn activity count is available, no personal site or contact form is listed, and no primary email is verified in the subject data. There are zero door-openers in the reachability index — no shared portfolio founders, no co-investors, no event co-speakers surfaced. The only realistic path to first contact is a warm introduction through the Anti Fund network or through founders who have previously received HVMN investment or advisory support; a founder should map their own network against Anti Fund's Crunchbase record before spending any time on outreach. Cold email or cold DM is almost certain (over 95%) to go unanswered given current activity signals (Confidence: Low — based on absence of activity, not confirmed non-response policy).
---
Headline Recommendation
Skip — until a warm introduction through the Anti Fund or HVMN founder network is secured, public data is too thin and reachability too closed to justify four weeks of active pursuit.